N
Nassim Kamar
Researcher at Paul Sabatier University
Publications - 696
Citations - 25605
Nassim Kamar is an academic researcher from Paul Sabatier University. The author has contributed to research in topics: Transplantation & Kidney transplantation. The author has an hindex of 73, co-authored 628 publications receiving 20442 citations. Previous affiliations of Nassim Kamar include French Institute of Health and Medical Research & Tabriz University of Medical Sciences.
Papers
More filters
Journal ArticleDOI
Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person.
Damien Guinault,David Ribes,Audrey Delas,David Milongo,Florence Abravanel,Florence Abravanel,Bénédicte Puissant-Lubrano,Jacques Izopet,Jacques Izopet,Nassim Kamar,Nassim Kamar +10 more
TL;DR: The first documented case of autochthonous HEV-induced cryoglobulinemic crescentic and membranoproliferative glomerulonephritis in an immunocompetent man with no notable medical history is reported, and HEV can cause severe kidney disease and should be considered in cases of unexplained glomerular disease.
Journal ArticleDOI
Dynamic Prognostic Score to Predict Kidney Allograft Survival in Patients with Antibody-Mediated Rejection
Denis Viglietti,Alexandre Loupy,Olivier Aubert,Oriol Bestard,Jean-Paul Duong Van Huyen,Jean-Luc Taupin,Denis Glotz,Christophe Legendre,Xavier Jouven,Michel Delahousse,Nassim Kamar,Carmen Lefaucheur +11 more
TL;DR: A dynamic composite prognostic ABMR score is defined to predict kidney allograft survival, integrating the disease characteristics at diagnosis and the response to treatment, and could be used to inform therapeutic decisions in clinical practice and for the design of clinical trials.
Journal ArticleDOI
Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation
Florence Abravanel,Jean-Michel Mansuy,Anne Huynh,Nassim Kamar,Laurent Alric,Jean-Marie Péron,Christian Recher,Jacques Izopet +7 more
TL;DR: The risk of HEV reactivation after stem cell transplantation appears to be very low, despite strong immunosuppression in pretransplant seropositive patients.
Journal ArticleDOI
High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation
Arnaud Del Bello,Nicolas Congy-Jolivet,Marie Danjoux,Fabrice Muscari,Laurence Lavayssière,Laure Esposito,Anne-Laure Hebral,Julie Belliere,Nassim Kamar +8 more
TL;DR: Tacrolimus-IPV could be a useful tool to identify patients with a greater risk of graft rejection and of developing a de novo DSA after liver transplantation.
Book ChapterDOI
Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy.
TL;DR: Combined antiviral therapy and immunosuppression may be the treatment of choice for patients with severe renal disease, i.e. nephrotic syndrome and/or progressive renal failure, or diseases that are refractory to anti-HCV therapy alone.